Karuna, which began clinical trials of a first-of-its-kind schizophrenia drug called KarXT in 2016, has grown rapidly from about 20 employees in 2020 to more than 300 today.
KarXT, a dual M1/M4 muscarinic agonist, represents the first new mechanism of action to treat schizophrenia in several decades, if approved
Submission is supported by data from three positive.
Founded Entity Karuna Therapeutics submits New Drug Application to U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia
If approved, KarXT will be the first new mechanism.